Evidence map›Paper›PMID 32004450›Full record

ArticleAmerican journal of human genetics2020

Allele-Specific QTL Fine Mapping with PLASMA.

Austin T Wang, Anamay Shetty, Edward O'Connor, Connor Bell, Mark M Pomerantz, Matthew L Freedman, Alexander Gusev

Abstract read
In one paragraph

Article in American journal of human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Austin T WangDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: atwang@mit.edu.
Anamay ShettyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Cambridge University, Cambridge CB2 1TN, UK.
Edward O'ConnorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Connor BellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mark M PomerantzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Alexander GusevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Brigham & Women's Hospital, Division of Genetics, Boston, MA 02215, USA. Electronic address: alexander_gusev@dfci.harvard.edu.

Funding

(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactionsR01CA227237 · NCI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER, ZAITLEN, NOAH A · 2018 to 2022
$3.5M
Defining the epigenetic landscape in human prostate cancerR01CA193910 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A, FREEDMAN, MATTHEW L · 2015 to 2019
$3.1M
Identifying causal variants and genes underlying breast cancer risk lociR01CA204954 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L · 2016 to 2020
$3.0M
Utilizing genetic and functional strategies to identify causal genes and allelesR01GM107427 · NIGMS · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, JOUNG, J. KEITH · 2014 to 2017
$2.0M
Efficient methods for identifying cryptic relatedness in millions of individualsR21HG010748 · NHGRI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER · 2019 to 2020
$372k
NCI NIH HHS R01 CA193910NCI NIH HHS R01 CA204954NCI NIH HHS R01 CA227237NHGRI NIH HHS R21 HG010748NIGMS NIH HHS R01 GM107427
6 · The paper itself

Abstract

Although quantitative trait locus (QTL) associations have been identified for many molecular traits such as gene expression, it remains challenging to distinguish the causal nucleotide from nearby variants. In addition to traditional QTLs by association, allele-specific (AS) QTLs are a powerful measure of cis-regulation that are concordant with traditional QTLs but typically less susceptible to technical/environmental noise. However, existing methods for estimating causal variant probabilities (i.e., fine mapping) cannot produce valid estimates from asQTL signals due to complexities in linkage disequilibrium (LD). We introduce PLASMA (Population Allele-Specific Mapping), a fine-mapping method that integrates QTL and asQTL information to improve accuracy. In simulations, PLASMA accurately prioritizes causal variants over a wide range of genetic architectures. Applied to RNA-seq data from 524 kidney tumor samples, PLASMA achieves a greater power at 50 samples than conventional QTL-based fine mapping at 500 samples, with more than 17% of loci fine mapped to within five causal variants, compared to 2% by QTL-based fine mapping, and a 6.9-fold overall reduction in median credible set size compared to QTL-based fine mapping when applied to H3K27AC ChIP-seq from just 28 prostate tumor/normal samples. Variants in the PLASMA credible sets for RNA-seq and ChIP-seq were enriched for open chromatin and chromatin looping, respectively, at a comparable or greater degree than credible variants from existing methods while containing far fewer markers. Our results demonstrate how integrating AS activity can substantially improve the detection of causal variants from existing molecular data.

Indexed as

AlgorithmsAllelic ImbalanceQuantitative Trait LociBiomarkers, TumorChromosome MappingComputer SimulationData Interpretation, StatisticalHumansKidney NeoplasmsLinkage DisequilibriumMalePhenotypePolymorphism, Single NucleotideProstatic NeoplasmsBiomarkers, Tumorallele-specificcausal variantChIP-seqcis-regulationfine-mappinggene regulationQTLregulatory variantRNA-seq

Identifiers

PMID32004450
PMCPMC7011109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.